Login to Your Account



Regulus roller coaster: Interim RG-101 data energize some investors while worrying others

By Michael Fitzhugh
Staff Writer

Friday, April 15, 2016

Renewed excitement over signs that RG-101, a microRNA-122 antagonist from Regulus Therapeutics Inc., could shorten the duration of several direct-acting antiviral treatment regimens for HCV to as little as four weeks boosted company shares briefly on Friday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription